Stone House Investment Management’s Design Therapeutics DSGN Stock Holding History

Stone House Investment Management’s Portfolio DSGN Stock Details DSGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.54K	Buy	+239	New	+$2.42K	﹤0.01%	559

Other funds holding DSGN

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Point72 Asset Management

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Stone House Investment Management's DSGN Position: Q1 2026 in Review

Stone House Investment Management opened a new position in Design Therapeutics (DSGN) in Q1 2026: 239 shares worth $2.54K. The stake represents ﹤0.01% of the portfolio and ranks #559 among its holdings.

125 funds tracked by Wall St. Rank hold DSGN as of Q1 2026.

Stone House Investment Management held 239 shares of Design Therapeutics worth $2.54K as of Q1 2026.
Design Therapeutics was a new Stone House Investment Management position in Q1 2026.
Design Therapeutics made up ﹤0.01% of Stone House Investment Management's portfolio in Q1 2026, its #559 holding.
125 funds tracked by Wall St. Rank held Design Therapeutics as of Q1 2026.

Based on Stone House Investment Management's 13F filing for Q1 2026, filed 22 Apr 2026.